GSD Venture Studios Podcasts by Gary Fowler
Join Dr. Simon MacKenzie, co-CEO of Cellbricks Therapeutics, for a grounded and high-stakes discussion on the reality of biofabrication. With over 25 years of experience building biotech and med-tech organizations across Europe, the US, and Asia, Simon is a veteran leader who knows that the gap between a "cool demo" and a "clinical therapeutic" is paved with disciplined engineering. In this episode, we strip away the hype of "printing organs overnight" to explore the hard work of creating vascularized, functional human tissues that can actually survive and integrate within the patient. 🎯 Insights You’ll Learn: The Hype vs. Reality Check: Where we truly stand in 2026—moving from lab-grown clusters to complex, implantable adipose and soft tissues. The Vascularization Challenge: Why the biggest hurdle isn't printing the cells, but building the "plumbing" (blood vessels) that keeps them alive once implanted. Stepwise Innovation: Why Cellbricks is focusing on soft tissue reconstruction and wound healing as the essential stepping stones to full organ replacement. AI-Powered Tissue Engineering: How deep learning and fluid dynamics are used to generate precise biological "building plans" that ensure tissue viability. The Business of Biofabrication: Navigating the translational valley—from raising €10M in recent funding to managing the manufacturing foundations for human-scale implants. Regenerative Partnerships: How collaboration between engineers, clinicians, and regulatory bodies is the only way to move bioprinting into the clinic. The Global Ecosystem: Lessons from building a "deep-tech" bridge between the innovation hubs of Berlin and Boston. 🌍 Why This Matters: For years, regenerative medicine has promised a world where we don't just treat symptoms, but replace damaged parts. However, in 2026, the industry is entering a new chapter: the shift from potential to proof. Simon MacKenzie and the team at Cellbricks are focused on "living tissue implants"—not synthetic compromises, but biological alternatives designed to restore function. By solving the engineering of complex bio-architectures today, Simon is laying the groundwork for a future where organ shortages could become a thing of the past. It’s a journey measured in disciplined milestones, not just headlines. 👤 Expert Background: Co-CEO of Cellbricks Therapeutics, leading therapeutic programs and translational development. PhD in Biochemistry from the University of Dundee with a career spanning 25+ years in life sciences. Former CEO at REGENHU, a leader in 3D bioprinting technology. Biotech Scale-up Specialist who has launched discovery and therapeutic programs across three continents. Strategic Mentor for startups in the regenerative and personalized medicine space. 🎙️ Hosted by Gary Fowler, CEO of GSD Venture Studios — global AI entrepreneur, investor, and innovation leader spotlighting founders navigating the realities of building in the AI era. 💡 Perfect For: Med-tech investors, regenerative medicine researchers, surgeons, biotech founders, and anyone interested in the technical and commercial hurdles of the "next frontier" of healthcare. 🚀 Timely Topic: The vision of printing a human heart is the north star, but the victory is won in the clinical validation of functional tissue today. Simon MacKenzie is the architect ensuring that the bridge to that future is built on solid biology and sound business. Subscribe for more global founder conversations from GSD Venture Studios: https://gsdvs.com #Bioprinting #RegenerativeMedicine #Cellbricks #TissueEngineering #HealthTech #SimonMacKenzie #GaryFowler #GSDVentureStudios
618 jaksot
Kommentit
0Ole ensimmäinen kommentoija
Rekisteröidy nyt ja liity GSD Venture Studios Podcasts by Gary Fowler-yhteisöön!